With advancements in understanding ROP pathology and the efficacy of VEGF inhibitors like bevacizumab in other eye diseases, such as in diabetic retinopathy [20] and age-related macular degeneration [21], anti-VEGF drugs became an option for ROP treatment. The gene discussed is VEGFA; the disease is diabetic retinopathy.